A Conversation With Liz Risenberg of Lumenis

Industry Insider<br>Liz Risenberg discusses the launch of the OptiLIFT device, the benefits it provides to ophthalmology practices, and what inspires her the most about the work the company does.

By
Julie Greenbaum, editor
January 1, 2026
4 min

Ophthalmology Management

At a Glance

Category	Detail
Condition	Lower Lid Laxity and Dry Eye Disease
Key Mechanisms	Dynamic Muscle Stimulation Technology (DMSt) strengthens periorbital muscles and improves eyelid function.
Target Population	Patients with lower lid laxity and symptomatic dry eye disease.
Care Setting	Ophthalmology practices.

Key Highlights

OptiLIFT addresses lower lid laxity through non-surgical muscle toning.
DMSt technology results in significant improvements in eyelid appearance and blinking quality.
60% of symptomatic dry eye patients suffer from impaired lid closure.

Guideline-Based Recommendations

Diagnosis

Assess lower lid laxity and its impact on blinking and ocular surface health.

Management

Utilize OptiLIFT for non-surgical treatment of lower lid laxity.

Monitoring & Follow-up

Evaluate improvements in tear breakup time and eyelid appearance post-treatment.

Risks

Consider potential need for surgical intervention in severe cases.

Patient & Prescribing Data

Patients experiencing dry eye symptoms related to lower lid laxity.

Protocol includes 4 treatments, 1 week apart, with each session lasting 7 minutes per side.

Clinical Best Practices

Incorporate DMSt technology into treatment plans for patients with lower lid laxity.
Educate patients on the benefits of addressing muscle aging in the periorbital area.